Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively engaging with investors and presenting its pipeline of biopharmaceutical products at the upcoming BIO CEO & Investor Conference, highlighting its focus on pain management and CNS disorders [1][2][3]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges [3]. - The company is advancing TNX-102 SL, a product candidate for fibromyalgia management, with a PDUFA goal date of August 15, 2025, for marketing authorization [3]. - TNX-102 SL has received Fast Track designation from the FDA and is also being developed for acute stress reaction and acute stress disorder [3]. Product Pipeline - Tonix's CNS portfolio includes TNX-1300, a biologic in Phase 2 development for cocaine intoxication, which has FDA Breakthrough Therapy designation [3]. - The immunology development portfolio includes TNX-1500, targeting CD40-ligand for organ transplant rejection and autoimmune diseases [3]. - The company is developing TNX-801, a vaccine for mpox, and has secured a contract with the U.S. DoD for up to $34 million to develop TNX-4200, broad-spectrum antiviral agents [3]. Commercial Operations - Tonix Medicines, the commercial subsidiary, markets Zembrace® SymTouch® and Tosymra® for the treatment of acute migraine in adults [3].